Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues: |
| Dronabinol SG Capsule | | | | | | | 6.9 | |
| Subsys | | | | | | | 8.6 | |
| Total revenues | 82.1 | 140.7 | 242.3 | 330.3 | 219.1 | 99.3 | 15.5 | 0.0 |
| Revenue growth | -41.7% | -41.9% | -26.7% | 50.8% | 120.7% | 541.6% | | |
| Cost of goods sold | 10.8 | 20.6 | 25.4 | 28.9 | 22.6 | 12.7 | 7.6 | 0.0 |
| Gross profit | 71.3 | 120.1 | 216.9 | 301.5 | 196.5 | 86.6 | 7.8 | 0.0 |
| Gross margin | 86.8% | 85.3% | 89.5% | 91.3% | 89.7% | 87.2% | 50.7% | |
| Selling, general and administrative [+] | 70.6 | 95.4 | 111.7 | 143.6 | 102.4 | 45.6 | 19.6 | 9.0 |
| Sales and marketing | 31.4 | 48.9 | 69.7 | 80.7 | 58.1 | 29.2 | 11.4 | |
| General and administrative | 39.3 | 46.5 | 42.1 | 62.9 | 44.3 | 16.4 | 8.2 | 9.0 |
| Research and development | 57.6 | 63.0 | 73.9 | 56.8 | 33.1 | 8.5 | 6.3 | 8.3 |
| Other operating expenses | 16.8 | 159.7 | 3.9 | -8.8 | -16.9 | -1.7 | | |
| EBITDA [+] | -66.1 | -190.6 | 33.6 | 115.2 | 80.4 | 36.1 | -16.4 | -16.0 |
| EBITDA growth | -65.3% | -667.8% | -70.9% | 43.2% | 123.0% | -320.2% | 2.4% | |
| EBITDA margin | -80.6% | -135.5% | 13.9% | 34.9% | 36.7% | 36.3% | -105.8% | |
| Depreciation and amortization | 7.6 | 7.3 | 6.2 | 5.3 | 2.5 | 1.8 | 1.7 | 1.4 |
| EBIT [+] | -73.7 | -197.9 | 27.3 | 109.9 | 77.9 | 34.3 | -18.0 | -17.4 |
| EBIT growth | -62.8% | -824.5% | -75.1% | 41.1% | 127.3% | -290.0% | 3.8% | |
| EBIT margin | -89.8% | -140.7% | 11.3% | 33.3% | 35.6% | 34.5% | -116.5% | |
| Non-recurring items [+] | 54.0 | 21.1 | 20.0 | 19.4 | 16.9 | 1.7 | 5.4 | |
| Asset impairment | | | | | | | 5.4 | |
| Legal settlement | 54.0 | 21.1 | 20.0 | | | | | |
| Interest expense, net [+] | -2.0 | -1.9 | -1.0 | -0.5 | -0.2 | 0.9 | 2.7 | 2.0 |
| Interest expense | | | | | | 1.0 | 2.7 | 2.0 |
| Interest income | 2.0 | 1.9 | 1.0 | 0.5 | 0.2 | 0.0 | | |
| Other income (expense), net [+] | -0.7 | 0.0 | 0.1 | 0.0 | 0.0 | -0.1 | 1.7 | 0.0 |
| Litigation settlement | | | | 10.6 | | | | |
| Other | -0.7 | 0.0 | 0.1 | 0.0 | 0.0 | -0.1 | 1.7 | |
| Pre-tax income | -126.4 | -217.2 | 8.4 | 91.0 | 61.1 | 31.6 | -24.4 | -19.4 |
| Income taxes | -1.9 | 9.6 | 0.8 | 32.9 | 25.1 | -8.8 | 0.0 | 0.0 |
| Tax rate | 1.5% | | 9.9% | 36.2% | 41.0% | | 0.0% | 0.0% |
| Net income | -124.5 | -226.8 | 7.6 | 58.1 | 36.1 | 40.4 | -24.4 | -1.6 |
| Net margin | -151.7% | -161.2% | 3.1% | 17.6% | 16.5% | 40.7% | -157.5% | |
| |
| Basic EPS [+] | ($1.68) | ($3.12) | $0.11 | $0.81 | $0.52 | $0.78 | ($2.62) | ($2.08) |
| Growth | -46.2% | -3047.6% | -86.9% | 54.6% | -32.7% | -129.8% | 25.9% | |
| Diluted EPS [+] | ($1.68) | ($3.12) | $0.10 | $0.77 | $0.49 | $0.70 | ($2.62) | ($2.08) |
| Growth | -46.2% | -3151.6% | -86.7% | 56.0% | -30.0% | -126.8% | 25.9% | |
| |
| Shares outstanding (basic) [+] | 74.1 | 72.6 | 71.6 | 71.6 | 68.8 | 51.8 | 9.3 | 0.8 |
| Growth | 2.0% | 1.4% | 0.1% | 4.1% | 32.6% | 456.5% | 1088.2% | |
| Shares outstanding (diluted) [+] | 74.1 | 72.6 | 74.2 | 75.7 | 73.3 | 57.5 | 9.3 | 0.8 |
| Growth | 2.0% | -2.1% | -2.0% | 3.2% | 27.6% | 516.9% | 1088.2% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|